The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Aim
To determine risk factors associated with hepatocellular carcinoma (HCC) development following direct‐acting antiviral (DAA) therapy.
Methods
We enrolled patients with chronic hepatitis C who underwent direct‐acting antiviral therapy and achieved sustained virologic response at 12 weeks between 2012 and 2018. Subsequently, patients were followed up. The primary endpoint was the development...
Aims
Mass‐forming intrahepatic cholangiocarcinomas (MF‐iCCAs), involving small bile ducts, bile ductules or canals of Hering, remain treated as a single entity. We aimed to examine the diversity in histology, phenotype and tumour vasculature of MF‐iCCAs.
Methods and results
Based on morphology and immunophenotype, we classified MF‐iCCAs into small bile duct (SBD), cholangiolocarcinoma (CLC), ductal...